<DOC>
	<DOCNO>NCT00722969</DOCNO>
	<brief_summary>Patients advance metastatic ( stage IIIB-IV ) non small cell lung cancer receive prior chemotherapy treat erlotinib 150 mg day sorafenib 400 mg twice day . The objective study assess efficacy safety combination treatment . Additional exploratory study objective correlation biomarkers image modality potentially predictive response ( progression free ) survival .</brief_summary>
	<brief_title>Erlotinib Sorafenib Chemonaive Patients With Locally Advanced Metastatic Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Histologically/cytologically advance NSCLC stage IIIB IV 2 . No prior chemotherapy therapy systemic antitumor therapy ( e.g. , monoclonal antibody therapy ) prior exposure agent direct HER axis ( e.g . EGFR TK inhibitor , Herceptin ) . Prior surgery and/or localize irradiation permit provide irradiated lesion measurable lesion . 3 . Age &gt; 18 year . 4 . ECOG Performance Status 0 1 5 . Life expectancy least 12 week . 6 . Subjects least one unidimensional ( RECIST ) measurable lesion . Lesions must measure CTscan . 7 . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : 8 . Hemoglobin &gt; 9.0 g/dl 9 . Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 10 . Platelet count &gt; 100,000/Î¼l 11 . Total bilirubin &lt; 1.5 time upper limit normal 12 . ALT AST &lt; 2.5 x upper limit normal ( &lt; 5 x upper limit normal patient liver involvement cancer ) 13 . Alkaline phosphatase &lt; 4 x ULN 14 . PTINR/PTT &lt; 1.5 x upper limit normal [ Patients therapeutically anticoagulated low molecular weight heparin allow participate provide prior evidence underlie abnormality parameter exist . ] 15 . Serum creatinine &lt; 1.5 x upper limit normal . 16 . Written informed consent . Excluded medical condition : 1 . History cardiac disease : congestive heart failure &gt; NYHA class 2 ; active CAD ( MI 6 mo prior study entry allow ) ; cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension . 2 . History HIV infection chronic hepatitis B C. 3 . Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) 4 . Symptomatic metastatic brain meningeal tumor ( unless patient &gt; 1 month definitive radiotherapy steroid ) : 5 . Patients seizure disorder require medication ( steroids antiepileptic ) 6 . History organ allograft . 7 . Patients evidence history bleed diathesis 8 . Patients undergoing renal dialysis 9 . Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis &amp; T1 ] cancer curatively treat &gt; 3 year prior study entry . Excluded therapy medication , previous concomitant : 1 . Anticancer chemotherapy immunotherapy study within 4 week study entry . 2 . Radiotherapy study within 3 week start study drug . ( Palliative radiotherapy allow ) . Major surgery within 3 week start study 3 . Autologous bone marrow transplant stem cell rescue within 4 month study 4 . Use biologic response modifier , GCSF , within 3 week study entry . [ GCSF hematopoietic growth factor may use management acute toxicity febrile neutropenia clinically indicate discretion investigator , however may substitute require dose reduction . ] [ Patients take chronic erythropoietin permit provide dose adjustment undertaken within 2 month prior study study ] 5 . Investigational drug therapy outside trial within 4 week study entry 6 . Prior exposure study drug . 7 . Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Both men woman enrol trial must use adequate barrier birth control measure course trial two week completion trial . 8 . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result 9 . Any condition unstable could jeopardize safety patient compliance study 10 . Patients unable swallow oral medication .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>erlotinib</keyword>
	<keyword>sorafenib</keyword>
</DOC>